Sergio Diaz
Family Medicine · McAllen, TXNPI 1740423474
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,098 of the $6,258 with a category attached, or 65.5%. 20 manufacturers reported payments, led by Astrazeneca UK Limited at 24.2% of the total. Reporting peaked in 2022 at $2,456 and has fallen 76.3% since, to $581 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $26.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$2K
- Shionogi Inc$1K
- AstraZeneca$630
- Novo Nordisk$619
- AbbVie$570
- Lilly USA, LLC$499
- plus $1K from 14 others
Across 8 payments — averaging $218.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2K
What the payments were for
- Travel & lodging$2,11934%
- Food & beverage$4,09865%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 3 | $1,513 |
| Shionogi Inc | 3 | $1,041 |
| AstraZeneca | 26 | $630 |
| Novo Nordisk | 45 | $619 |
| AbbVie | 36 | $570 |
| Lilly USA, LLC | 42 | $499 |
| Amgen | 29 | $363 |
| Abbott | 11 | $345 |
| GSK | 18 | $288 |
| Otsuka America Pharmaceutical, Inc. | 4 | $88 |
| Dexcom, Inc. | 4 | $80 |
| Astellas Pharma US Inc | 3 | $50 |
| Genentech USA, Inc. | 3 | $34 |
| Indivior Inc. | 1 | $29 |
| Halozyme Inc | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,258 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 246 | $308,638 |
| SynjardyEmpagliflozin/Metformin Hcl | 134 | $109,198 |
| FarxigaDapagliflozin Propanediol | 91 | $101,277 |
| MyrbetriqMirabegron | 98 | $74,822 |
| LinzessLinaclotide | 57 | $42,333 |
| ProliaDenosumab | 23 | $36,857 |
| JardianceEmpagliflozin | 34 | $34,441 |
| Xigduo XrDapaglifloz Propaned/Metformin | 27 | $31,820 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $27,550 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $22,400 |
| VraylarCariprazine Hcl | 17 | $22,362 |
| TradjentaLinagliptin | 22 | $22,235 |
| MounjaroTirzepatide | 21 | $22,176 |
| RybelsusSemaglutide | 16 | $20,949 |
| EliquisApixaban | 15 | $20,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $619 | $329,587262 claims |
| AstraZenecaFarxiga | $630 | $101,27791 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $74,82298 claims |
| AbbVieLinzess, Vraylar | $570 | $64,69574 claims |
| AmgenProlia | $363 | $36,85723 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $288 | $34,23761 claims |
| Lilly USA, LLCMounjaro | $499 | $22,17621 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $88 | $18,19713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in McAllen
- Joel SolisMcAllen$324K
- Enrique GriegoMcAllen$179K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.